Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.
News & Analysis: Pluristem Therapeutics
The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sangamo Biosciences, Inc.
Today's top stories in healthcare and biotech.
Sinovac, Pluristem, and Synta Pharmaceuticals might all be worth a look today. Let's take a look at the headlines that could move these three stocks.
Market-lagging returns could be written in this 1-Star.
Medifast, Questcor, and Pluristem all fell.
Will this stock make short work of short sellers?
A look at the biggest stories this week in biotech and what they mean for investors.
Market-lagging returns could be written in this one star.
Analysts see value in Halliburton and Motorola Solutions, but less in Pluristem.